US › Healthcare

DarioHealth Corp (DRIO)

US · Healthcare · Health Information Services

$6.99+3.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$5.2M

Revenue YoY

-3.6%

Net profit

$-7.9M

EPS

$-0.85

EPS estimate

$-1.19

Net margin

-153.1%

EPS came in at -0.85 against a street estimate of -1.19 — a beat of 28.6%.

Key statistics

Market cap

$67.9M

Forward P/E

10.6

P/B

1.23

Book value

$7.50

EPS (TTM)

$-14.87

52-week high

$17.74

52-week low

$5.84

50-day MA

$7.18

200-day MA

$8.84

Beta

1.12

Analyst view

Analysts rate DarioHealth Corp a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $14.00.

Shareholding

Insiders

15.88%

Institutions

9.10%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	6.23%
Vanguard Capital Management, LLC	0.67%
Geode Capital Management, LLC	0.63%
Vanguard Fiduciary Trust Co	0.31%
Citadel Advisors Llc	0.25%
BlackRock Inc	0.19%
UBS Group AG	0.16%
Northern Trust Corp	0.14%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DarioHealth Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.